ArticleFrontiers in cell and developmental biology2025
Fufang Duzhong Jiangu granule (FFDZ) ameliorates osteoarthritis development through maintaining subchondral bone homeostasis.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a widespread joint disorder predominantly marked by cartilage degeneration and the hardening of subchondral bone, with a lack of disease-modifying drugs for OA treatment. Fufang Duzhong Jiangu granule (FFDZ), a Chinese medicine, has demonstrated efficacy and safety in the clinical management of OA patients. However, the precise mechanisms through which it operates are still not fully understood. Methods: In this study, we set out to explore the protective effects of FFDZ on destabilization of the medial meniscus (DMM) surgery-induced OA mice and elucidate its mechanism underlying the delay of OA progression both Results: We observed that FFDZ administration effectively attenuated cartilage degradation and subchondral bone deterioration at 8 weeks after DMM operation. Gait analysis indicated that FFDZ could alleviate OA pain caused by surgery. Notably, FFDZ exhibited a potent inhibitory effect on osteoclast activity, as evidenced by tartrate-resistant acid phosphatase (Trap) staining, and repressed the osteoblastic expression of osterix and alkaline phosphatase (ALP) increasing after DMM operation in subchondral bone area. Subsequently, we confirmed that FFDZ reduced the number of CD44 Discussion: In summary, this study demonstrated that FFDZ decelerated OA development in knee joints of mice after DMM potentially by maintaining subchondral bone homeostasis, providing evidences for the further application of FFDZ as an OA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.